ArticleInternational journal of pharmaceutics: X2026
Immunostimulant-integrated acrylate nanocomposite adjuvants potentiate foot-and-mouth disease vaccine efficacy.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) is a viral infectious disease of artiodactyls that threatens the global livestock economy and public health security. Vaccination is employed to prevent the occurrence of infectious diseases, and adjuvants play a key role in vaccine preparation. Commercially available FMD vaccines mainly use oil-emulsion adjuvants that induce a humoral immune response in the body. Based on the acrylate hydrogel adjuvant (AHN) with sustained-release properties, this study introduced CpG, Poly I:C, and QS-21 immunostimulants to create an prepare immunostimulant-integrated acrylate nanocomposite adjuvant (AHN@X) combining excellent antigen delivery capability and immune response direction regulation for use in FMD vaccines. AHN@X has a particle size of less than 100 nm, and it exhibits good storage stability at 4 °C. The FMD vaccines prepared with AHN@X nanocomposite adjuvant were immunized by intramuscular injection in BALB/c mice. The results showed that it could efficiently induce specific IgG, IgG1 and IgG2a antibody titers and activate B cells and T cells. Moreover, AHN@C stimulated splenocytes to secrete cytokines IFN-γ and IL-4 at the highest concentrations, 58.34 pg/mL and 32.24 pg/mL respectively. Additionally, the AHN@C nanocomposite adjuvant promoted the strongest endocytosis of antigens by macrophages, and it efficiently induced humoral immune responses and cellular immune responses. Overall, the clinical protective efficacy of AHN@C against FMDV is worth subsequent validation in target livestock animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.